Spero Therapeutics, Inc.

NasdaqGS:SPRO 株式レポート

時価総額:US$74.0m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Spero Therapeutics バランスシートの健全性

財務の健全性 基準チェック /66

Spero Therapeuticsの総株主資本は$96.2M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$167.7Mと$71.5Mです。 Spero Therapeuticsの EBIT は$27.0Mで、利息カバレッジ比率-6.3です。現金および短期投資は$82.3Mです。

主要情報

0%

負債資本比率

US$0

負債

インタレスト・カバレッジ・レシオ-6.3x
現金US$82.27m
エクイティUS$96.25m
負債合計US$71.45m
総資産US$167.70m

財務の健全性に関する最新情報

Recent updates

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Apr 23

Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Mar 12
Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Jan 02
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

May 18
Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Apr 17
Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

Apr 13
Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Apr 05
We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value

Oct 03

Spero Therapeutics appoints Kamal Hamed MD CMO

Sep 15

Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate

Sep 06

Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M

Aug 10

We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

Jul 04
We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely

Mar 17
We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely

Sizing Up Spero Therapeutics

Oct 15

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) CEO Compensation Looks Acceptable To Us And Here's Why

Aug 11
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) CEO Compensation Looks Acceptable To Us And Here's Why

財務状況分析

短期負債: SPROの 短期資産 ( $140.2M ) が 短期負債 ( $41.8M ) を超えています。

長期負債: SPROの短期資産 ( $140.2M ) が 長期負債 ( $29.6M ) を上回っています。


デット・ツー・エクイティの歴史と分析

負債レベル: SPROは負債がありません。

負債の削減: SPRO 5 年前には負債がありませんでした。

債務返済能力: SPROには負債がないため、営業キャッシュフロー でカバーする必要はありません。

インタレストカバレッジ: SPROには負債がないため、利息支払い の負担は問題になりません。


貸借対照表


健全な企業の発掘